Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Apremilast. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B known ✓ | Q07343 | 20/20 | 1.00 |
| ▸ | PDE4C known ✓ | Q08493 | 19/20 | 1.00 |
| ▸ | PDE4A known ✓ | P27815 | 13/20 | 1.00 |
| ▸ | PDE4D known ✓ | Q08499 | 13/20 | 1.00 |
| ▸ | HTR2B | P41595 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Apremilast SCHEMBL302671 | 1.00 | PDE4B (1.00) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| Apremilast SCHEMBL302992 | 1.00 | PDE4B (1.00) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| Apremilast SCHEMBL29393225 | 1.00 | PDE4B (1.00) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| Apremilast SCHEMBL29446192 | 1.00 | PDE4B (1.00) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| Apremilast SCHEMBL29392757 | 1.00 | PDE4B (1.00) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| Apremilast SCHEMBL29350625 | 1.00 | PDE4B (1.00) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| Apremilast SCHEMBL15869338 | 1.00 | PDE4B (1.00) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| Apremilast SCHEMBL7135116 | 1.00 | PDE4B (1.00) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| Apremilast SCHEMBL15869341 | 1.00 | PDE4B (1.00) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| Apremilast SCHEMBL25247853 | 0.99 | PDE4B (0.98) | PDE4BPDE4CPDE4APDE4DHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2235213-A2 | USE OF MICRO-RNA AS A BIOMARKER OF IMMUNOMODULATORY DRUG ACTIVITY | CELGENE CORPORATION (US) | 2010-10-06 | — | — | EP | disclosed |
| WO-2009085234-A9 | USE OF MICRO-RNA AS A BIOMARKER OF IMMUNOMODULATORY DRUG ACTIVITY | CELGENE CORPORATION (US) | 2010-08-12 | — | — | WO | disclosed |
| WO-2009085234-A2 | USE OF MICRO-RNA AS A BIOMARKER OF IMMUNOMODULATORY DRUG ACTIVITY | SIGNAL PHARMACEUTICALS, INC. (US) | 2009-07-09 | — | — | WO | disclosed |